AXS-05 Phase 3 Results for Alzheimer's Agitation

Axsome released phase 3 results today from their ongoing clinical trial evaluating AXS-05 for agitation associated with Alzheimer's disease. Currently there is no drug approved for this unmet need. The results below were good, with a rapid and substantial effect. The complete press release is at Axsome.com.

• Cohen Mansfield (CMAI) total score at 5 weeks, p=0.010 versus placebo
• Week 3 compared to placebo p=0.007
• Well tolerated and not associated with cognitive impairment or sedation